27 results about "Foam cell" patented technology

The invention provides a preparation method of an ADC foaming agent for improving foaming pore density, which comprises the following steps: step 1, mixing a modified inorganic nucleating agent with water according to a predetermined mass ratio, adding a dispersing agent, and uniformly mixing to prepare uniform and stable suspension slurry to prevent agglomeration of the nucleating agent; 2, when the conversion rate of the biurea reaches 80%-85%, adding the suspension slurry, so that the inorganic nucleating agent is uniformly attached to the surface of the ADC crystal; and 3, continuing the oxidation reaction until the biurea conversion rate reaches 92% or above, and then washing, centrifuging and drying to obtain the ADC foaming agent. The ADC foaming agent for improving the foaming pore density is prepared by the method. The inorganic nucleating agent is added in the stage of preparing the ADC foaming agent, and compared with the inorganic nucleating agent added in the subsequent foam material preparation process, the density of foaming pores can be remarkably improved.

Provided are a metal-organic framework nanomaterial, a preparation method therefor, and a use thereof, belonging to the technical field of bionanomaterials, and resolving the technical problem of inhibiting atherosclerosis using biomimetic metal-organic framework nanoenzymes. The solution is: the components of the of the metal-organic framework nanomaterial and the ratio thereof are: metal ions Ce4+ and a ligand fumaric acid in a molar ratio of 1:5. The preparation method therefor is: measuring an FA regulator and water to prepare a mixed solution, then adding fumaric acid and cerium ammonium nitrate dropwise into the mixed solution, stirring at room temperature, centrifuging, repeatedly washing alternately with water and ethanol, and finally drying overnight in a vacuum oven. A simple, efficient and convenient method for synthesizing the metal-organic framework nanomaterial is provided. The synthesized metal-organic framework nanomaterial has excellent CEH-like enzyme activity and intrinsic antioxidant activity, and can be used to increase lipid efflux and reduce lipid uptake, and decrease ox-LDL-induced foam cell formation, thereby alleviating atherosclerosis.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

The present application discloses foamable compositions comprising cellulose acetate and a combination of a carbon dioxide as a physical blowing agent and a chemical blowing agent. The foamable compositions are used to prepare foams that exhibit lower density, lower average foam cell size, and fewer corrugations than foams made only by carbon dioxide.

This invention discloses a biomimetic nanocomposite, its preparation method, and its application in the preparation of products for treating atherosclerosis, belonging to the field of pharmaceutical preparation technology. The biomimetic nanocomposite is an Ir-TiO2 metal nanozyme encapsulated in an M2 macrophage membrane. This invention prepares a structurally biomimetic nanocomposite by coating Ir-TiO2 nanoparticles with an M2 macrophage membrane. After intravenous injection, the formed biomimetic nanocomposite actively targets endothelial cells in atherosclerotic lesions, releasing Ir-TiO2 antagonistically into the cytoplasm of plaque-containing endothelial cells and inflammatory macrophages. Once Ir-TiO2 reaches the lesion site, it exerts an enzymatic effect to achieve anti-inflammatory activity and promotes cholesterol excretion from inflammatory cells such as macrophages and smooth muscle cells at the lesion site, reducing intracellular lipid deposition, reducing foam cell formation, and promoting plaque growth. This nanotherapy can effectively prevent the progression of inflammation in atherosclerotic lesions and alleviate atherosclerosis.

The utility model relates to the technical field of elastomers, in particular to a supercritical foaming elastomer drying device which comprises a shell, the shell comprises a feeding pipe, a transmission frame, a screen frame, a motor, a transmission structure and a discharging pipe, the feeding pipe is fixed to the top end of the shell, the transmission frame is fixedly connected to the inner top end of the shell, and the motor is fixedly connected to the bottom end of the shell. Through sieving, uneven heating or local degradation during drying can be avoided, and the material purity is guaranteed; for the high-hygroscopicity elastomer, the subsequent foaming defect caused by impurity adsorption can be reduced through sieving; the particle uniformity is optimized, elastomer particles with uniform particle sizes can be screened out through screening, it is ensured that the heat transfer efficiency and the moisture escape efficiency are consistent in the drying process, and the drying effect is improved; the uniform particles are easier to form a stable gas saturation state in the supercritical fluid, so that the uniformity of subsequent foaming cells is facilitated.

The invention provides a supercritical nitrogen high-temperature and high-pressure silica gel foaming device and a material thereof, and relates to the technical field of methyl vinyl silicone rubber. Supercritical nitrogen is adopted to replace a chemical foaming agent, a core process link of pre-crosslinking curing is realized through silica gel foaming UV ultraviolet radiation process parameters, and a parameter system is based on a photoinitiator system and depends on a UV-A wave band light source; by accurately controlling the irradiation dose, high-efficiency and low-heat-damage industrial production extrusion molding, segmented swelling, three-section type pressure reduction and secondary segmented crosslinking processes are realized, and the problems of non-uniform cells, chemical residues and the like in a traditional method are solved. According to the silicone rubber with the process adaptive density of 100-200 kg / m < 3 >, different process parameters are adopted according to different densities, nano calcium carbonate is added to serve as a nucleating agent, the product performance is excellent, and the silicone rubber can be applied to the high-end fields such as 5G chip cushions and aerospace damping liners and has high economic value and good application prospects.

This invention relates to the field of cardiovascular disease research technology, and particularly to the application of the NOD1 inhibitor ML130 in hypoxia-induced macrophage polarization, including the use of ML130 in the preparation of drugs that regulate hypoxia-induced macrophage polarization. These drugs inhibit the NOD1 / RIP2 signaling axis and can be used to intervene in the formation and progression of atherosclerotic plaques. This invention creatively combines the NOD1 inhibitor ML130 with the hypoxic microenvironment of atherosclerotic plaques, specifically inhibiting the NOD1 / RIP2 signaling pathway and directly regulating macrophage polarization balance; reducing the accumulation of pro-inflammatory cells in unstable plaque areas, inhibiting foam cell formation and necrotic core expansion, significantly improving plaque stability, and reducing the risk of serious cardiovascular events such as acute coronary syndrome; it clarifies that ML130 exerts its effect by blocking the NOD1 / RIP2-NF-κB / MAPK signaling axis, exhibiting high target specificity and avoiding the side effects of broad-spectrum inhibition by traditional anti-inflammatory drugs.

To provide a molded component of uneven thickness that is lightweight yet has excellent strength and appearance.　A molded component 1 is made of a thermoplastic resin and comprises a base 2 and first ribs 6. The base 2 has a thin part 3, a thick part 4, and a step part 5 formed between the thin part 3 and the thick part 4. The first ribs 6 protrude from one surface 3a of the thin part 3 in the thickness direction of the thin part 3 and contact the step part 5. The ratio of foam cells in the thin part 3 is 0-5%. The ratio of foam cells in the thick part 4 is 5-50%. A width W of the base of the first ribs 6 is 1.0 times or more the average thickness t1 of the thin part 3. The ratio of the foam cells in the first ribs 6 is from more than 0% to 90%.

The invention relates to the technical field of cell targeted therapy, in particular to a construction method of OPN-targeted chimeric antigen receptor mononuclear macrophages and application of the OPN-targeted chimeric antigen receptor mononuclear macrophages to removal of foam cells. The chimeric antigen receptor mononuclear macrophage targeting OPN is a mononuclear macrophage of which a cell membrane is integrated with a chimeric antigen receptor of which the nucleotide sequence is as shown in SEQ ID NO.7. The invention further discloses a preparation method of the chimeric antigen receptor mononuclear macrophage. Different from a technical path of only targeting membrane protein in a traditional CAR therapy, the method innovatively selects secreted protein OPN as a target spot, and realizes accurate recognition and efficient removal. The strategy breaks through the technical prejudice that secreted protein cannot be used as an effective CAR target spot, formed foam cells can be directly removed, and the lesion process is reversed. According to the technical scheme, the technical problem that a safe and effective method for removing foam cells is lacked in the prior art can be solved, and the traditional Chinese medicine composition is remarkably superior to an existing lipid-lowering or anti-inflammatory therapy and has an outstanding treatment effect and a wide clinical application prospect.

The invention provides an application of bazedoxifene in preparation of a medicine for promoting motor function recovery after spinal cord injury. Specifically, the invention provides an application of an active component, the active component is selected from bazedoxifene, or pharmaceutically acceptable salts thereof, or active derivatives thereof, and the active component is used for preparing a medicine or a kit for preventing and / or treating motor function recovery disorder after spinal cord injury. Or the active ingredient is used for preparing a preparation or a composition, and the preparation or the composition is used for inhibiting synaptic loss caused by lipid accumulation in foam cells.

The invention belongs to the technical field of basic medicine scientific research, and particularly relates to a method for rapidly constructing a mouse atherosclerosis model by using sorafenib. According to the method, the original molding period of 12 weeks or longer is shortened to 8 weeks, and the problem of long molding time is successfully solved; in addition, the atherosclerosis mouse model constructed by the method has a very remarkable atherosclerosis effect (the blood fat levels TC, TG and HDL-C are higher); the atherosclerotic aorta plaque area is larger, the blood vessel stenosis is more serious, and foam cells in the aortic valve are increased.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses bovine serum albumin coated Prussian blue drug-loaded nanoparticles as well as a preparation method and application thereof, the drug-loaded nanoparticles are bovine serum albumin coated Prussian blue drug-loaded nanoparticles, and curcumin (Curcumin, Curr) is co-loaded to the surface of Prussian blue through hydrophobic interaction to obtain the drug-loaded nanoparticles. According to the drug-loaded nanoparticles provided by the invention, the accumulation and retention time of the drug in an atherosclerosis microenvironment can be remarkably prolonged. Passive targeting can be realized after intravenous injection administration, Prussian blue and curcumin are released at an inflammation part, Prussian blue clears active oxygen at the inflammation part by virtue of own enzyme-like activity, 808 nanometer laser irradiation is assisted, Prussian blue exerts a photothermal effect to increase excretion of lipid in foam cells, and in combination with the anti-inflammatory characteristic of curcumin, the anti-inflammatory effect of Prussian blue is improved. The treatment effect is improved.

This invention relates to the field of nanobubble technology, specifically to a macrophage membrane-modified cationic lipid nanobubble loaded with SHP-1 inhibitor, its preparation method, and its applications. This macrophage membrane-modified cationic lipid nanobubble loaded with SHP-1 inhibitor is constructed by using cationic lipid nanobubbles as the core carrier, electrostatically adsorbing and loading SHP-1 inhibitor, and further modifying it with a macrophage membrane. It not only possesses excellent physicochemical properties, a high cell membrane modification rate, and a high membrane protein retention rate, but also exhibits a high targeted uptake rate of M1 macrophages with an inflammatory phenotype in in vitro models. Furthermore, it promotes lipid efflux from foam cells and demonstrates good biocompatibility.

The invention belongs to the field of medicines for treating atherosclerosis, and particularly discloses application of miR-187-3p in preparation of medicines for treating atherosclerosis, the sequence of a positive-sense strand of miR-187-3p mimic is shown as SEQ ID NO.1, and the sequence of an antisense strand of miR-187-3p mimic is shown as SEQ ID NO.2. The invention further discloses a preparation method of the medicine for treating atherosclerosis. Compared with the prior art, the invention discloses a new regulatory axis inhibited by LOX-1, and miR-187-3p mimic can be used for weakening macrophage inflammation and foam cell formation induced by ox-LDL by directly targeting a LOX-1 receptor; in a mouse body, the administration of agomiR-187-3p obviously reduces the expression of LOX-1 and reduces the plaque load; the result shows that the miR-187-3p mimic can be used for preparing the medicine for treating the atherosclerosis.

The invention belongs to the technical field of application of natural compounds, and particularly relates to novel application of aescin. Aescin is applied to preparation of the atherosclerosis medicine for cardiovascular diseases, reduction of AMPK phosphorylation induces increase of p-mTOR expression, reduction of autophagy causes accumulation of cholesterol in macrophage-derived foam cells, and finally occurrence and development of atherosclerosis are promoted. According to the application, AMPK is activated through aescin, mTOR phosphorylation is reduced to induce autophagy of the macrophage-derived foam cells, ABCA1 protein expression is up-regulated, cholesterol outflow of the macrophage-derived foam cells is promoted, and therefore atherosclerosis is improved.

The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and / or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and / or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal / medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.

This invention discloses a foamed EPDM rubber material, comprising the following raw materials in parts by weight: 100 parts EPDM rubber, 0.5-5 parts vulcanizing agent, 0.5-6 parts accelerator, 2-15 parts vulcanizing activator, 0.5-3 parts lubricant, 0-200 parts reinforcing agent, 0.5-10 parts foaming agent, 0.5-3 parts reduced graphene and graphene oxide, and 0.5-2 parts bisphenol A epoxy resin. The rubber composition is obtained by blending these components and further processed into sealing strips. The technical solution of this invention utilizes two-dimensional graphene material to effectively "fix" the cured foam cells, and employs bisphenol A epoxy resin to regulate the concentrated distribution of graphene on the inner wall of the foam cells, thereby improving the shrinkage and compression properties of the EPDM foam material.

The invention relates to a ZIF-8 nano-enzyme with a Ce-luteolin coordination coating as well as a preparation method and application of the ZIF-8 nano-enzyme, and belongs to the technical field of biological medicines and nano-materials. The nano enzyme is constructed by adopting a step-by-step loading-coordination assembly strategy: firstly, synthesizing ZIF-8 nano particles as an inner core; then luteolin is introduced and adsorbed to pores and the surface of ZIF-8; finally, cerium ions are introduced, and the dense Ce-luteolin metal-organic coordination coating is formed on the surface of the ZIF-8 through in-situ growth by means of the strong coordination effect of phenolic hydroxyl groups and carbonyl groups in luteolin molecules and the cerium ions. The nano-enzyme has excellent SOD-like and CAT-like activities, and effectively inhibits foam cell formation, regulates endothelial cell senescence-related secretory phenotype (SASP) and alleviates DNA damage through an ROS removal-anti-inflammatory-anti-aging synergistic mechanism. The invention provides a new multi-target nano intervention strategy for the treatment of atherosclerosis.

The application provides a preparation method of an ADC foaming agent for improving foaming cell density, which comprises the following steps: step 1: mixing a modified inorganic nucleating agent and water according to a predetermined mass ratio, adding a dispersing agent, uniformly mixing, and preparing a uniform and stable suspension slurry to prevent the nucleating agent from agglomerating; step 2: when the conversion rate of biurea reaches 80%-85%, the suspension slurry is added, and the inorganic nucleating agent is uniformly attached to the surface of the ADC crystal; step 3: continuing the oxidation reaction until the conversion rate of biurea reaches more than 92%, and then performing washing, centrifugation and drying to obtain the ADC foaming agent. The ADC foaming agent for improving foaming cell density is prepared by the above method. In the preparation process of the ADC foaming agent, the inorganic nucleating agent is added, compared with adding the inorganic nucleating agent in the subsequent preparation process of the foaming material, and the foaming cell density can be significantly improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of 4-octyl itaconic acid in preparation of a medicine for preventing and treating AS. In-vivo and in-vitro model research finds that 4-octyl itaconic acid further promotes ABCA1 expression by activating an NRF2-HO-1 / NQO1 antioxidant network, promoting formation of an NQO1-p53 compound, blocking ubiquitination degradation of p53 and improving p53 stability, so that cholesterol excretion of VSMCs is enhanced, formation of foam cells is reduced, and AS plaque lipid deposition is remarkably relieved. The invention systematically reveals the action mechanism of 4-OI in AS lesion for the first time, and provides a new treatment strategy and theoretical basis for early intervention of AS.

This invention discloses a method for preparing hirudin-tanshinone B self-assembled nanoparticles for reversing foam cell regeneration, belonging to the field of nanomedicine formulation technology. The method includes: dispersing hirudin (HV) and tanshinone B (SaB) in pure water at a mass ratio; adding zinc chloride solution dropwise under constant temperature stirring at a mass ratio of zinc chloride to the total mass of hirudin and tanshinone B; using zinc ions as a bridging medium, driving hirudin and tanshinone B to self-assemble into nanoparticles through non-covalent interactions; and obtaining the nanoparticles after solid-liquid separation. This invention achieves efficient co-loading of peptides and polyphenolic active molecules through a metal ion coordination-driven self-assembly strategy. The resulting nanoparticles have uniform particle size and good stability, significantly reducing lipid deposition in foam cells and enhancing their cellular burial function, thus reversing the function of foam cells to normal macrophages.

The application provides a cerium-zirconium and arginine nano composite drug targeting an arterial vulnerable plaque microenvironment and preparation and application thereof, including L-arginine, solid cerium-zirconium nanozyme, bone bridge protein short peptide and a liposome carrier. The mass ratio of the L-arginine, the solid cerium-zirconium nanozyme and the bone bridge protein short peptide is 2:5:2, and the mass ratio of the liposome carrier and the total of the three substances is 1:1600-1800. The application innovatively uses a slow-release preparation technology to complete the encapsulation of the cerium-zirconium nanozyme and basic L-arginine, realizes neutralization of a plaque microenvironment, and realizes specific treatment of foam cells through surface modification of bone bridge protein for targeted release of drugs. The compound realizes anti-aging treatment of atherosclerosis, has a small particle size, high biocompatibility, a simple and mature process, low material cost, is stable and reliable, and is a convenient, safe and ideal way for treating AS.

The invention belongs to the technical field of biological medicines, particularly relates to application of PLIN3 in preparation of a medicine for improving or inhibiting foaming of vascular smooth muscle cells, and provides a new strategy for improving foaming of the vascular smooth muscle cells. Vascular smooth muscle cell foaming is a key process of atherosclerosis development. The exploration process of the PLIN3 for improving vascular smooth muscle cell foaming comprises the following steps: 1) constructing a foamed cell model; 2) screening and determining treatment targets; and 3) the specific effect of the PLIN3 in regulating and controlling the lipid homeostasis of the vascular smooth muscle cells. Researches find that the knock-down of the PLIN3 can effectively reduce lipid accumulation of vascular smooth muscle cells, the over-expression of the PLIN3 obviously promotes intracellular lipid accumulation, and the PLIN3 plays an important role in maintaining a cell lipid steady state. Therefore, the medicine targeting the PLIN3 has application potential in the aspect of preventing and treating the atherosclerosis and other lipid metabolism syndromes.

The application discloses application of MLN4924 and flubendazole in preparation of drugs for treating atherosclerosis. Low-dose MLN4924 and flubendazole have little cytotoxicity, and both can treat atherosclerosis by interfering with the formation of foam cells and cholesterol accumulation; when MLN4924 and flubendazole are used in combination, the effect is stronger, and synergy is achieved.

This invention relates to the field of polymer materials technology, specifically disclosing a high-strength UV-resistant foamed polypropylene material and its preparation method. The invention involves covalently grafting amino-terminated polydimethylsiloxane (PDMS) onto polypropylene segments. The low surface tension of the PDMS reduces the nucleation barrier of the foam cells and improves the stability of the foam walls, resulting in a uniform and dense closed-cell structure. Then, octyl p-aminobenzoate is used to chemically graft nano-TiO2, improving the dispersion and interfacial compatibility of inorganic particles in the matrix. When the foamed material is subjected to stress, the foam structure disperses stress, the flexible PDMS segments dissipate energy, and the rigid TiO2 bears the load, achieving a three-level synergy of "foam stabilization, toughening, and strengthening," significantly improving the tensile strength of the foamed material. Simultaneously, nano-TiO2 and octyl p-aminobenzoate form broadband UV protection, and the Si-O-Si structure constructs a highly stable protective layer, synergistically endowing the material with excellent weather resistance and aging resistance.